一项评估 Mosunetuzumab 单药治疗在特定 B 细胞恶性肿瘤参与者中的安全性、有效性和药代动力学的研究 (MorningSun)
一项开放标签、多中心、II 期试验,评估皮下注射 Mosunetuzumab 单一疗法在特定 B 细胞恶性肿瘤患者中的安全性、有效性和药代动力学
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alabama
-
Mobile、Alabama、美国、36607-3513
- Infirmary Cancer Care
-
-
Alaska
-
Anchorage、Alaska、美国、99508
- Alaska Oncology & Hematology, LLC
-
-
Arizona
-
Phoenix、Arizona、美国、85054-4504
- Mayo Clinic Arizona
-
-
California
-
Duarte、California、美国、91010
- City of Hope
-
-
Colorado
-
Aurora、Colorado、美国、80012-5405
- Rocky Mountain Cancer Centers (Aurora) - USOR
-
-
Delaware
-
Newark、Delaware、美国、19713-2055
- Medical Oncology Hematology Consultants
-
-
Florida
-
Fort Myers、Florida、美国、33916
- SCRI Florida Cancer Specialists South
-
Jacksonville、Florida、美国、32224-1865
- Mayo Clinic Jacksonville - PPDS
-
Jacksonville、Florida、美国、32256
- Cancer Specialists of North Florida - Jacksonville
-
St. Petersburg、Florida、美国、33705-1449
- Florida Cancer Specialists - NORTH - SCRI - PPDS
-
West Palm Beach、Florida、美国、33401-3406
- Florida Cancer Specialists - EAST - SCRI - PPDS
-
-
Iowa
-
Des Moines、Iowa、美国、50314-3030
- Mission Blood and Cancer - MercyOne Cancer Center
-
-
Kansas
-
Westwood、Kansas、美国、66205
- University of Kansas Medical Center
-
-
Louisiana
-
Zachary、Louisiana、美国、70791
- Oncology Hematology Care - SCRI
-
-
Maryland
-
Bethesda、Maryland、美国、20817-1915
- American Oncology Partners of Maryland, PA
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic - PPDS
-
-
Montana
-
Billings、Montana、美国、59101
- St. Vincent Frontier Cancer Center
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- Astera Cancer Care East Brunswick
-
-
New Mexico
-
Farmington、New Mexico、美国、87401
- San Juan Oncology Associates
-
-
New York
-
Albany、New York、美国、12206
- New York Oncology Hematology, P.C.
-
New Hyde Park、New York、美国、11042-1116
- New York Cancer & Blood Specialists - New Hyde Park
-
New York、New York、美国、10028-0506
- NY Cancer & Blood Specialist
-
Shirley、New York、美国、11967
- North Shore Hematology Oncology Association PC
-
The Bronx、New York、美国、10469-5930
- New York Cancer & Blood Specialists - Bronx
-
-
Ohio
-
Cincinnati、Ohio、美国、45236-2725
- Oncology Hematology Care Inc - Cincinnati - USOR
-
-
Oregon
-
Eugene、Oregon、美国、97401
- Oncology Associates of Oregon, P.C.
-
Portland、Oregon、美国、97227
- Kaiser Foundation Hospitals
-
Portland、Oregon、美国、97213-2933
- Providence Cancer Institute
-
-
Pennsylvania
-
West Reading、Pennsylvania、美国、19611
- McGlinn Cancer Institute at Reading Hospital
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37404-3230
- Tennessee Oncology Chattanooga
-
Nashville、Tennessee、美国、37203
- Tennessee Oncology - Nashville
-
-
Texas
-
Amarillo、Texas、美国、79124-2167
- Texas Oncology (Amarillo) - USOR - 1826 Point West Pkwy
-
Austin、Texas、美国、78705
- Texas Oncology-Austin Midtown
-
Dallas、Texas、美国、75246-2008
- Texas Oncology (Worth) - USOR
-
Tyler、Texas、美国、75702-8363
- Texas Oncology (Tyler) - USOR
-
-
Virginia
-
Gainesville、Virginia、美国、20155-3257
- Virginia Cancer Specialists - Gainsville
-
-
Washington
-
Kennewick、Washington、美国、99336-7774
- Kadlec Clinic Hematology and Oncology
-
Seattle、Washington、美国、98108-1532
- VA Puget Sound Health Care System - NAVREF - PPDS
-
Spokane、Washington、美国、99218-8205
- MultiCare Deaconess Cancer and Blood Specialty Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least one bi-dimensionally measurable nodal lesion, defined as >1.5 cm in its longest dimension, or one bi-dimensionally measurable lesion, defined as >1.0 cm in its longest diameter by computed tomography (CT) scan, positivie emission tomography - computed tomography (PET- CT), or magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- Adequate hematologic function
- No active infection
- Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/µL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
- For women of childbearing potential (except those in Cohort B): agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as defined by the protocol
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined by the protocol
Inclusion Criteria Specific to Cohorts A1 and A2
- Previously untreated FL with indication to start systemic therapy
- Adequate renal function
Inclusion Criteria Specific to Cohort B
- Aged ≥ 80 years at the time of signing informed consent form (ICF), or aged 65-79 years and considered ineligible for chemoimmunotherapy (R-CHOP) with at least one of the following: Impairment in ≥ 2 Activities of Daily Living (ADL); impairment in ≥ 2 Instrumental Activities of Daily Living (IADL); or Cumulative Illness Rating Scale-Geriatric (CIRS-G) score of ≥ 1 comorbidity with a severity of 3-4 or a score of 2 in ≥ 8 comorbidities
- Histologically confirmed DLBCL according to WHO 2016 classification expected to express the CD20 antigen (Swerdlow et al. 2016)
- Previously untreated DLBCL with indication to start systemic therapy and are not eligible for curative therapy
- High-grade B-cell lymphomas, not otherwise specified (HGBL NOS) and HGBL with MYC and B-cell lymphoma (BCL)-2 and/or BCL-6 rearrangements
- Adequate end-organ function
Inclusion Criteria Specific to Cohort C
- Histologically conformed MZL (splenic, nodal, and extra-nodal)
- Previously untreated MZL with indication to start systemic therapy
- Helicobacter pylori-positive disease that has remained stable, progressed, or relapsed following antibiotic therapy and requires therapy, as assessed by the investigator (for cases of gastric/MALT MZL)
- Adequate renal function
Inclusion Criteria Specific to Cohort D
- Histologically confirmed MCL
- Relapsed after or failed to respond to at least one prior treatment regimen containing a Bruton's tyrosine kinase (BTK) inhibitor
- Adequate renal function
- Adverse events from prior anti-cancer therapy resolved to Grade </= 1
Inclusion Criteria Specific to Cohort E
- Histologically confirmed RT or tFL
- Relapsed after or failed to respond to at least one prior systemic treatment regimen for RT or tFL
- Adequate renal function
- Absolute lymphocyte count </= 5000 uL
- Adverse events from prior anti-cancer therapy resolved to Grade </= 1
Exclusion Criteria:
- Current or past history of central nervous system (CNS) lymphoma or leptomeningeal infiltration
- Prior treatment with mosunetuzumab
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Known active SARS-CoV-2 infection
- Known or suspected chronic active Epstein-Barr virus (CAEBV) infection
- Patients with history of macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH)
- Positive test results for chronic hepatitis B infection (HBV), acute or chronic hepatitis C virus (HCV) infection, or known or suspected HIV infection
- Administration of a live, attenuated vaccine within 4 weeks before first mosunetuzumab administration or anticipation that such a live, attenuated vaccine will be required during the study
- Prior solid organ transplantation
- Prior allogenic stem cell transplant
- Treatment with CAR-T therapy within 30 days prior to C1D1
- History of autoimmune disease, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
- Received systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment </= 10 mg/day prednisone or equivalent within 2 weeks prior to the first dose of mosunetuzumab
- Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks before C1D1
- Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
- Recent major surgery within 4 weeks before the start of C1D1, other than superficial lymph node biopsies for diagnosis
- Prior treatment with radiotherapy within 2 weeks prior to C1D1
- Adverse events from prior anti-cancer therapy not resolved to Grade </= 1 (with the exception of alopecia, anorexia, nausea, vomiting, and fatigue)
- Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
- History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies (MAbs)
- Contraindication to tocilizumab
- Prior anti-lymphoma treatment with monoclonal antibodies, radioimmunoconjugates, or antibody-drug conjugates within 4 weeks before first mosunetuzumab administration
Exclusion Criteria Specific to Cohorts D and E
- Prior anti-lymphoma treatment with any monoclonal antibody (e.g., anti-CD20), radioimmunoconjugate, or antibody-drug conjugate therapy within 4 weeks before first mosunetuzumab administration
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort A
Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year. |
Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only) Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab |
|
实验性的:Cohort B
Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. |
Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only) Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab |
|
实验性的:Cohort C
Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. |
Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only) Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab |
|
实验性的:Cohort D
Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. |
Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab Participants will receive SC mosunetuzumab for up to 34 cycles |
|
实验性的:Cohort E
Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. |
Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab Participants will receive SC mosunetuzumab for up to 34 cycles |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
首次研究治疗后 24 个月的无进展生存 (PFS) 率(队列 A1、A2 和 B)
大体时间:从第一次研究治疗到第一次出现疾病进展、复发或任何原因导致的死亡,以先发生者为准,由研究者根据 2014 年卢加诺标准确定(至少 2 年)
|
从第一次研究治疗到第一次出现疾病进展、复发或任何原因导致的死亡,以先发生者为准,由研究者根据 2014 年卢加诺标准确定(至少 2 年)
|
|
客观反应率 (ORR),定义为具有完全代谢反应 (CMR) 或部分反应 (PR) 的参与者比例,由研究者根据 2014 年卢加诺标准(队列 C、D 和 E)确定
大体时间:第 4、8、12 和 17 周期(周期长度 = 21 天)
|
第 4、8、12 和 17 周期(周期长度 = 21 天)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
总生存期 (OS)(所有队列)
大体时间:从第一次研究治疗到因任何原因死亡(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
从第一次研究治疗到因任何原因死亡(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
|
ORR,定义为研究者根据 2014 年卢加诺标准(队列 A1、A2 和 B)确定的 CMR 或 PR 参与者的比例
大体时间:第 4、8、12 和 17 周期(周期长度 = 21 天)
|
第 4、8、12 和 17 周期(周期长度 = 21 天)
|
|
响应时间 (TTR)(所有队列)
大体时间:对于达到 CMR 或 PR 的患者,从第一次研究治疗到第一次出现有记录的客观反应(队列 A1-C 至少 2 年,队列 D 和 E 至少 1 年)
|
对于达到 CMR 或 PR 的患者,从第一次研究治疗到第一次出现有记录的客观反应(队列 A1-C 至少 2 年,队列 D 和 E 至少 1 年)
|
|
反应持续时间 (DOR)(所有队列)
大体时间:从第一次出现有记录的对疾病进展的客观反应或任何原因导致的死亡,以先发生者为准(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
从第一次出现有记录的对疾病进展的客观反应或任何原因导致的死亡,以先发生者为准(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
|
CMR 最佳反应参与者的 DOR(所有队列)
大体时间:从 CMR 记录到进展或死亡时间,以先发生者为准(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
从 CMR 记录到进展或死亡时间,以先发生者为准(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
|
完全缓解持续时间 (DoCR)(所有队列)
大体时间:从 CMR 记录到进展或死亡时间,以先发生者为准(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
从 CMR 记录到进展或死亡时间,以先发生者为准(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
|
发生不良事件 (AE) 的参与者百分比(所有队列)
大体时间:队列 A-C 至少 2 年或队列 D 和 E 至少 1 年
|
队列 A-C 至少 2 年或队列 D 和 E 至少 1 年
|
|
Mosunetuzumab 的血清浓度(所有队列)
大体时间:周期 1 第 1、2、8、15 天;此后第 2、3、4、6、8、12、16 周期的第 1 天(周期长度 = 21 天)
|
周期 1 第 1、2、8、15 天;此后第 2、3、4、6、8、12、16 周期的第 1 天(周期长度 = 21 天)
|
|
下次治疗时间 (TTNT)(所有队列)
大体时间:从首次研究治疗到开始新的抗淋巴瘤治疗 (NALT) 或死亡(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
从首次研究治疗到开始新的抗淋巴瘤治疗 (NALT) 或死亡(队列 A1-C 至少 2 年或队列 D 和 E 至少 1 年)
|
|
PFS(所有队列)
大体时间:从第一次研究治疗到第一次出现疾病进展、复发或任何原因导致的死亡,以先发生者为准,由研究者根据 2014 年卢加诺标准确定(队列 A1-C 至少 2 年,队列 D、E 至少 1 年)
|
从第一次研究治疗到第一次出现疾病进展、复发或任何原因导致的死亡,以先发生者为准,由研究者根据 2014 年卢加诺标准确定(队列 A1-C 至少 2 年,队列 D、E 至少 1 年)
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ML43389
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.